We sought to investigate the factors associated with restenosis and its potential association with late clinical deterioration after successful percutaneous mitral valvuloplasty (PMV).
Introduction
Percutaneous mitral valvuloplasty (PMV) is a logical extension of surgical closed commissurotomy for mitral stenosis (MS). 1 Compared with surgical treatments, PMV resulted in dramatic haemodynamic improvements and similar post-procedural benefits, 2, 3 leading to PMV becoming a standard treatment option for symptomatic patients with pliable morphology of the mitral valve. 4 -10 The increased clinical applications of this invasive procedure and cumulative clinical experience have been accompanied by significant improvements in its success rate and safety. The procedural success of PMV, however, is based on clinical and echocardiographic outcome studies with relatively short follow-up durations (i.e. ,5 years).
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Development of restenosis after successful PMV is a challenging issue and it was already reported in an early clinical investigation that restenosis could occur within 1 year after successful PMV. 19 Although significant mitral regurgitation (MR) after PMV, another serious complication of the procedure, is expected to be stationary or decrease during follow-up, 19 ,20 development of restenosis is time-dependent, 14, 21, 22 which is represented in the wide range of reported restenosis incidence (from 4 to 39%) according to the different follow-up duration. 3,6,14,16,19,23 -25 The observation of progressive decrease of mitral valve area (MVA) in rheumatic MS with 14, 22, 26 or without PMV 27, 28 can raise serious questions regarding the current definition of procedural success or optimal result. Since MS patients with a MVA !1.5 cm 2 are generally considered to have mild stenosis and to be relatively asymptomatic, this value has been chosen as the threshold for definition of procedural success. 29 The potential clinical impact of time-dependent MVA decrease during long-term follow-up was not included in this definition. Moreover, relative importance of pre-procedural echocardiographic score vs. quality of the immediate results including MVA in predicting restenosis is not well defined 14, 16, 18, 21, 22 and controversial reports are available for the relationship between restenosis and long-term clinical outcome. 15, 22 Absence of regular echocardiographic follow-up data and relatively short follow-up duration of the previous reports might have contributed as serious confounding factors. Considering gradual deterioration of functional class and a continued risk of mitral valve surgery after PMV 13, 17, 30 with relatively sharp deterioration of functional status 5 years after successful PMV, 13, 17 longer clinical observation is required to accurately assess the procedural success of PMV. We have therefore performed a long-term clinical and echocardiographic outcome study to assess the factors associated with longterm success after PMV and to test the predictive value of the quality of the immediate results.
Methods Subjects
The study involved consecutive patients in our institution who underwent PMV with the Inoue balloon technique owing to haemodynamically significant MS between 1 January 1995 and 31 December 2000.
Patients with a prior history of PMV or commissurotomy were excluded and a total of 402 patients (301 women: mean age 44 + 11 years) with mean MVA 1.0 + 0.2 cm 2 and total echocardiographic score 7.3 + 1.3 underwent PMV during the study period. Procedural success, defined as MVA !1.5 cm 2 and MR 2/4, was achieved in 329 patients (82%) and they were the subjects of this study.
Percutaneous mitral valvuloplasty
After cardiac catheterization confirmed severe MS without significant MR, experienced physicians performed PMV using the Inoue balloon technique while monitoring the conventional haemodynamic parameters. Balloon size was chosen to obtain an effective balloon dilation area/body surface area of approximately 4 cm 2 /m 2 , and one-step dilation was performed.
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Echocardiographic evaluation
Comprehensive two-dimensional and colour Doppler echocardiographic evaluation was performed in all patients on the day before and 24 h after PMV, using a Hewlett-Packard Sonos 2500 or 5500 imaging system equipped with a 2.5-MHz transducer. The morphological features of the mitral valve were categorized as described previously, and the total echocardiographic score was obtained by adding the scores for leaflet mobility, thickness, calcification, and subvalvular lesions. 31 MVA was measured by direct planimetry at the parasternal short-axis view, and pulmonary artery systolic pressure was estimated by continuous wave Doppler echocardiography using the modified Bernoulli equation [4Â(peak tricuspid regurgitant jet velocity) 2 ] with 10 mmHg added for the estimated right atrial pressure. MVA measurement by two-dimensional planimetry was done on the day after PMV, and the mitral gradient and the peak pressure gradient of tricuspid regurgitation were calculated. In addition, the extent of the commissurotomy or separation of the commissures, primarily at the parasternal short-axis and the apical two-chamber view, were assessed along with the development of MR. The echocardiographic criterion of successful commissurotomy or commissural splitting was the development of new echocardiographic dropout in the region of one or both commissures at the maximal opening ( Figure 1A and B) . Diagnosis of commissural MR was based on a clearly definable jet of MR originating at the site of successful commissurotomy ( Figure 1C and D 
Data analysis
All statistical analyses were performed with SPSS (version 12.0), R (version 2.8.0.), and SAS (version 9). Categorical variables were presented as numbers and percentages, and were compared using x 2 or
Fisher's exact test. Continuous variables were expressed as mean + SD, and the Student unpaired t-test was used for comparison. The conventional definitions of procedural success (a MVA !1.5 cm 2 and MR ,3/4) and restenosis (follow-up MVA 1.5 cm 2 ) after PMV were used, and clinical and echocardiographic variables were compared between groups. Multivariable logistic regression analysis was used to identify factors associated with procedural success. For analysis of cumulative incidence of restenosis, patients with non-cardiovascular death were censored, whereas those with cardiovascular death were counted as a competing cause of failure. The cumulative incidence was calculated using Kalbfleisch and Prentice's method. 33 Clinical event-free survival rates were estimated by the Kaplan-Meier method and compared by the log-rank test. All baseline and echocardiographic variables were initially analysed using univariate Cox proportional hazards model to examine the relationship with restenosis and clinical events. The linearity assumption for the continuous variables was tested using Harrell's SAS Macro Psplinet (http://biostat. mc.vanderbilt.edu/twiki/bin/view/Main/SasMacros, 1991). As immediate post-PMV MVA for predicting restenosis and clinical events were violated for linearity assumption, we categorized immediate post-PMV MVA according to the 30th and 70th percentiles using the result of Post-PMV MVA as a prognosticator restricted cubic Spline Cox regression analysis. To ascertain whether immediate post-PMV MVA and commissural MR or splitting are independent predictors of restenosis and clinical events, hazard ratio (HR) and 95% confidence interval (CI) were calculated with the Cox proportional hazard models adjusted for the age, total echocardiographic score, and cardiac rhythm, which were known to be important predictors of the outcome. 11 -13,15 -18 Schoenfeld residuals and the log [2log(survival rate)] were used to verify that the proportional-hazard assumptions were not violated. Model fit was assessed through the use of residual analyses. To assess the cut-off point of immediate post-PMV MVA for predicting restenosis and clinical events within 5 years after successful PMV, receiver-operating characteristic (ROC) curves were used; we excluded censoring data within 5 years and development of restenosis and clinical events after 5 years was censored. The optimal cut-off value was defined as the value with the maximal sum of sensitivity and specificity. The reported 95% CI for cut-off points, area under the curve, sensitivities, and specificities were obtained through bootstrap with percentile method (200 replicates). All reported probability values were twotailed, with ,0.05 considered statistically significant.
Results
Immediate outcome
PMV was completed successfully in 401 of 402 patients; the remaining one patient underwent emergency mitral valve replacement immediately after PMV because of the development of severe MR, but subsequently died. PMV resulted in significant increase of MVA from 1.0 + 0.2 to 1.9 + 0.3 cm 2 (P , 0.001), and a significant decrease of mitral gradient from 12 + 6 to 5 + 2 mmHg (P , 0.001). Splitting of one or both commissures was observed in 308 patients (77%) and commissural MR in 294 patients (73%). Procedural success (MVA !1.5 cm 2 and MR 2/ 4) was achieved in 329 patients (82%). Baseline clinical, echocardiographic, and haemodynamic characteristics were compared in patients who did and did not achieve procedural success ( Table 1 ). The unsuccessful PMV group was characterized by higher echocardiographic score, larger left atrium, smaller pre-PMV MVA, and higher prevalence of atrial fibrillation than the successful PMV group. Backward logistic regression analysis identified smaller MVA [odds ratio (OR) ¼ 0.07, 95% CI ¼ 0.02-0.27, P , 0.001] and larger left atrial anterior -posterior diameter (OR ¼ 1.07, 95% CI ¼ 1.03 -1.11, P ¼ 0.001) as independent predictors of immediately unsuccessful results.
Restenosis
Regular echocardiographic follow-up data were available in 285 of the 329 patients (87%) who achieved procedural success after PMV. Restenosis was confirmed in 75 patients and progressively increased with observational duration (Figure 2 ). The 1, 3, 5, 7, and 9 year rates of restenosis-free survival were 99 + 1%, 97 + 1%, 95 + 1%, 86 + 3%, and 72 + 4%, respectively. Figure 3A ). MVA loss after successful PMV was variable, with a mean of 0.03 + 0.14 cm 
Clinical events
Follow-up data to confirm cardiovascular death or clinical events (mitral valve surgery or repeat PMV) were available for all patients with successful PMV result. During clinical follow-up, 12 patients (3.6%) died owing to various cardiovascular reasons, four of congestive heart failure, five of cerebrovascular accidents, one of infective endocarditis, one of acute myocardial infarction, and one who died suddenly. In addition, 24 patients underwent subsequent open heart surgery for the mitral valve and nine patients repeat PMV without mortality. Thus, clinical events, defined as cardiovascular deaths, repeat PMV, and mitral valve surgery, developed in 45 patients (13.7%). The 1, 3, 5, 7, and 9 year rates (mean + SE) of event-free survival after PMV were 99.7 + 0.3%, 96.4 + 1.0%, 94.5 + 1.3%, 90.8 + 1.6%, and 90.0 + 1.7%, respectively. MVA cut-off value for predicting development of clinical events after successful PMV was 1.9 cm 2 (95% CI ¼ 1.7 -2.0), which showed a sensitivity of 72% (95% CI ¼ 33-89) and a specificity of 58% (95% CI ¼ 44-86, Figure 3B ). The event-free survival rates were significantly different according to the immediate post-PMV MVA ( Figure 4) . The 3, 5, 7, and 9 year rates of event-free survival after PMV in patients with immediate post-PMV MVA ,1.8 cm 2 were 92.9 + 1.5%, 85.5 + 2.2%, 76.8 + 2.9%, and 67.2 + 3.7%, respectively with sharp decrease of event-free survival rate especially 5 years after successful PMV. Patients who developed restenosis after successful PMV showed lower event-free survival rate and rapid decrease of event-free survival rate 5 years after successful PMV was also noticed in these patients ( Figure 5 ).
Discussion
The present observational study found that development of restenosis after successful PMV was time-dependent and was associated with development of major clinical events, defined as cardiovascular death, mitral valve surgery, and repeat PMV after successful PMV. The immediate post-PMV MVA, reflecting the quality of the procedure, was the most important independent continuous variable predicting the development of both restenosis and major clinical events. Immediate post-PMV MVA !1.8 cm 2 was an important predictor of both restenosis-and clinical eventfree survival and this value should be considered as a component of optimal result.
Necessity for a new definition of optimal result after percutaneous mitral valvuloplasty
Among the prerequisites needed to define procedural success in clinical practice are that the value should be simple to obtain and should predict long-term adverse outcomes and/or event-free survival. The current definition of successful PMV (post-PMV MVA !1.5 cm 2 and MR 2/4), however, does not fulfil these requirements. Rather, this binary definition of procedural success is arbitrary. In early clinical experience with PMV, most patients were critically ill; therefore, a post-PMV MVA of 1.0 cm 2 or more was considered a 'good' result. 29 As clinical experience increased, patients with less severe MS underwent the procedure, including some with MVA .1.0 cm 2 before PMV. This necessitated a change in the absolute valve area that could be considered optimal. Since MS patients with a MVA !1.5 cm 2 are generally considered to have mild stenosis and to be relatively asymptomatic, this value was chosen as the threshold. 29 Using this definition, the procedural success of PMV was reported to range from 70 to 90%, 12, 14, 17, 21 with the event-free survival rate dependent on procedural success. 15, 21 Recent guidelines expanding the clinical application of PMV to less severe MS patients recommended a maximum MVA for considering PMV of 1.5 cm 2 . 34 Thus, for patients with MVA close to 1.5 cm 2 before PMV, a minimal increase would have classified the PMV as successful. This led to the inclusion of a second requirement, a !25% increase of MVA after PMV, but this cut-off value was also arbitrary and makes determination of procedure success more complicated. Time-dependent development of restenosis after initial haemodynamic improvement provides another criterion for procedural success. The incidence of restenosis has been reported to range from 4 to 39% 3,6,14,16,19,23 -25 and progressive decrease of MVA over time has been welldocumented. 14, 19 Moreover, restenosis was found to be strongly associated with poor long-term functional results after good immediate results 15 and relatively sharp functional deterioration or progressive development of adverse clinical events 5 years after PMV 12, 17 has been reported in long-term outcome studies.
These findings indicate the importance of long-term outcomes in defining the procedural success of PMV.
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Immediate post-percutaneous mitral valvuloplasty mitral valve area as a prognosticator pre-procedural factor determining procedural success, as well as being an independent factor determining event-free survival. 11 -13,15 -18 These findings have been very useful in selecting appropriate candidates for PMV, with a standard guideline of echocardiographic score 8. Although the percentage of patients with suboptimal outcomes increases as echocardiographic score increases, a high echocardiographic score does not preclude the possibility of a good result. 29 Thus, in re-defining the adequacy or quality of a procedure, procedural success, based on long-term clinical outcome, might be as important as pre-procedural risk factors. Long-term outcome in patients undergoing PMV is multifactorial, incorporating two important components: preprocedural risk factors and post-procedural variables reflecting the quality of the procedure. Among the pre-procedural risk factors are age, 13, 15, 17, 18 echocardiographic score, 11 -13,15 -18 cardiac rhythm, 15, 16 and New York Heart Association functional class, 11, 15, 17 whereas immediate post-PMV MVA and MR 12,14 -16 are associated with long-term outcomes. The strong predictive value of the quality of the immediate results has been reported in mid-term follow-up studies 14, 15, 30 and immediate post-PMV MVA is a useful non-invasive parameter to quantify the adequacy of a procedure as a continuous variable. In a study with a follow-up duration of 39 + 23 months, procedural results (immediate post-PMV MVA and MR) were found to be the only independent predictor of major event-free survival after PMV and an MVA!1.8 cm 2 was a good negative predictor of restenosis. 14 In another study with a follow-up duration of 2.3 + 1.5 years, echocardiographic score and immediate post-PMV MVA were independent predictors of event-free survival, 12 but no optimal cut-off value was determined. 12 The relatively short follow-up times of these two studies, however, may be associated with the failure to demonstrate the real prognostic power of immediate post-PMV MVA.
In our outcome study with a follow-up duration of 109 + 24 months, restenosis was associated with development of adverse clinical events after successful PMV and immediate post-PMV MVA was an independent predictor of both restenosis and clinical events. These findings indicate that the prognostic significance of immediate post-PMV MVA should be re-appraised. Moreover, we also found that immediate post-PMV MVA!1.8 cm 2 was a good negative predictor of both restenosis and adverse clinical outcome, and using the cut-off value of 1.8 cm 2 we have proved that the event-free survival rates were remarkably different even after achievement of successful PMV (Figure 4) . Patients with immediate post-PMV MVA ,1.8 cm 2 showed characteristic sharp decrease of survival rates, especially 5 years after successful PMV, which was already reported by other investigators. 12, 17 For the adverse clinical events, we did not include non-fatal cerebrovascular accidents or peripheral embolic episodes, which are also serious events in MS patients even after PMV. We believe that the procedural success is not the only variable associated with development of these events, as there are many confounding variables including rhythm, age, and poor compliance of anticoagulation. It is not certain if immediate post-PMV MVA can be a good prognosticator of clinical outcomes including all these soft events.
In our study, baseline echocardiographic score was not an independent predictor of procedural success and development of restenosis or clinical events. We believe this is related with selection bias. In a recent report of long-term outcome after PMV, the mean echocardiographic score of 879 patients was 7.7 + 2.2 and 32% had echocardiographic score .8. 17 However, in our study, the mean echocardiographic score was 7. 
Limitations
Regular long-term echocardiographic follow-up was not possible in all patients and this might have affected the restenosis rate and the best immediate post-PMV MVA cut-off value for prediction of restenosis. Of the 329 patients who successfully underwent PMV, 44 (13%) without regular echocardiographic follow-up were censored. Although a comparison of the 285 patients with and the 44 without regular echocardiographic follow-up found no significant differences in demographic, baseline, and immediate post-PMV echocardiographic variables, this does not constitute that lack of follow-up data occurs completely at random. This should be considered in the interpretation of our data. However, as we could check whether adverse clinical events occurred in all patients including these 44 without echocardiographic follow-up, we believe that our data supporting the prognostic role of immediate post-PMV MVA predicting clinical outcomes are solid. The ROC curves for events as a function of restenosis is problematic as the restenosis is a progressive event and the restenosis rates are changing over time. Thus, we applied the curve to get the best cut point to predict restenosis and adverse clinical events within 5 years. Different cut point might be obtained with different observational duration. However, we believe that this limitation does not mitigate the important predictive power of the immediate post-PMV MVA.
Another limitation of our study is that we failed to identify the mechanism of restenosis after successful PMV. Although many clinical studies report similarly high procedural success rates, they often differ in age, heterogeneity, prevalence of atrial fibrillation, and restenosis rates. 14, 16, 18, 19, 22, 37 Restenosis is gradual and progressive in nature, suggesting that this process involves more than a simple recoiling mechanical phenomenon after the initial stretch. In addition, restenosis rates are higher in Western countries, with a higher mean patient age, than in Asian and African countries, precluding the possibility that active recurrent rheumatic fever contributes to restenosis. The association of age and echocardiographic score with restenosis may reflect an immunologic or degenerative response with progressive valve injury triggered by PMV. Our finding that MVA decrease was dependent on immediate post-PMV MVA, which was an independent predictor of restenosis, suggests that 'suboptimal result' or procedural failure might be a better description for patients whose immediate post-PMV MVA was ,1.8 cm 2 .
Some technical limitations need to be addressed. We used a fixed value of 10 mmHg as an estimate for central venous pressure, which is not ideal. However, we believe that this is not likely to affect our main results and conclusions. Recently, the feasibility and accuracy of MVA measurement using three-dimensional echocardiography has been reported, 38, 39 and the potential additive value of this new approach remains to be evaluated.
Conclusions
The expanded clinical application of PMV to patients with less severe MS suggests a need to re-define the current definition of successful PMV (immediate post-PMV MVA !1.5 cm 2 and MR 2/4), and to test the prognostic power of the new definition in a long-term outcome study. In this long-term echocardiographic and clinical follow-up study, we found that development of restenosis after successful PMV was time-dependent and was associated with development of major clinical events (cardiovascular death, mitral valve surgery, and repeat PMV) after PMV. Immediate post-PMV MVA, a marker of procedural adequacy, was the most important independent continuous variable predicting both restenosis and major clinical events. The immediate post-PMV MVA !1.8 cm 2 was an excellent negative predictor of both restenosis and clinical events, and our findings indicate that this value should be used as a component for the new definition of optimal result.
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